Orexigen Therapeutics Inc. fell the most in three years after regulators pushed back a decision on whether to approve the company’s obesity drug NB32.
3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037
All contents herein copyright San Diego Source | The Daily Transcript ® 1994-2015